Search Results for 'Metastatic Psa'

Sipuleucel -T Survival Benefit

• calandra-battersby
• 0 Slides

Sipuleucel. -T was approved based on HR of 0.775 ...

Matthew D. Galsky, MD Director, GU Medical Oncology

• luanne-stotts
• 0 Slides

Tisch. Cancer Institute. Icahn School of Medicin...

Raising the Bar in the Management of Advanced/Metastatic NSCLC

• debby-jeon
• 0 Slides

Dr Tan . Jiunn. Liang. Clinical Specialist (Resp...

SARC020 – EORTC 62091 TRUSTS – A phase IIb/III multicenter study comparing the efficacy of TRab

• tatiana-dople
• 0 Slides

Study PI: James Butrynski, MD. Dana . Farber. Ca...

Dose finding designs driven by immunotherapy outcomes with Application to a metastatic melanoma pha

• lois-ondreau
• 0 Slides

Elizabeth Garrett-Mayer, PhD. Cody Chiuzan, MS. H...

Differentiating Among the CDK 4/6 Inhibitors in the Management of Metastatic Breast Cancer

• min-jolicoeur
• 0 Slides

This program will include a discussion of off-lab...

To date, several case reports have demonstrated response to therapy targeting the PD1 / PD-L1 axis

• test
• 0 Slides

PD-L1 is a transmembrane protein involved in regu...

ADVANCES IN THERAPY FOR SARCOMA AND GIST

• ellena-manuel
• 0 Slides

Angela . Cioffi. , MD. Sarcoma Research Program c...

NY-ESO-1 Specific T Cell Therapy for Patients with Metastatic Sarcoma

• giovanna-bartolotta
• 0 Slides

Seth M. Pollack, . MD. Associate in Clinical Rese...

As it pertains to the last patient in your practice who died of metastatic nonsquamous

• kittie-lecroy
• 0 Slides

non-small cell lung cancer (NSCLC) . with no targ...

Low TPS High TPS TPS = PD-L1 tumor proportion score Low TPS = 10%; high TPS = 60%

• olivia-moreira
• 32 Slides

Low TPS High TPS TPS = PD-L1 tumor proportion sco...

From Adjuvant to Metastatic in Melanoma This program will include a discussion of off-label treatment and investigational agents not approved by the FDA for use in the US, and data that were presented in abstract form.

• phoebe-click
• 29 Slides

From Adjuvant to Metastatic in Melanoma This pro...

Phase I Study of Olaparib and Temozolomide, in patients with recurrent and/or metastatic Ewing

• alexa-scheidler
• 15 Slides

Phase I Study of Olaparib and Temozolomide, in pa...

ADVANCED PROSTATE CANCER: BONE ISSUES AND METASTASES

• min-jolicoeur
• 58 Slides

ADVANCED PROSTATE CANCER: BONE ISSUES AND METASTA...

What’s Positive about Triple Negative Breast Cancer

• myesha-ticknor
• 55 Slides

What’s Positive about Triple Negative Breast Ca...

Targeting endocrine-resistance pathways in breast cancer

• alexa-scheidler
• 48 Slides

Targeting endocrine-resistance pathways in breas...

Management of HER2 Over-Expressed Breast Cancer in the Adjuvant, Neoadjuvant, and Metastatic settings

• marina-yarberry
• 68 Slides

Management of HER2 Over-Expressed Breast Cancer i...

Phase I Study of Olaparib and Temozolomide, in patients with recurrent and/or metastatic Ewing

• karlyn-bohler
• 15 Slides

Phase I Study of Olaparib and Temozolomide, in pa...

Hormone Receptor Positive Metastatic Breast Cancer

• pamella-moone
• 80 Slides

. 5/9/2017. The Lancet July 11, 1895. ON THE TRE...

Endocrine Treatment of Metastatic Breast Cancer: New Advances; Patient Education Implications

• calandra-battersby
• 74 Slides

An Interactive Oncology Grand Rounds Series. Joyc...

Please note, these are the actual video-recorded

• min-jolicoeur
• 67 Slides

proceedings from the live CME event and may inclu...

Please note, these are the

• disclaimercanon
• 72 Slides

actual. . video-recorded proceedings from the . l...

Biology and Treatment of Breast Cancer

• ripplas
• 23 Slides

Julie R. Gralow, M.D.. Director, Breast Medical On...

Proteomics of Tissue Tropism in Breast

• heartfang
• 26 Slides

Cancer (mostly). Lauren Barney. Peyton Lab. March ...

Eribulin Mesylate + Trastuzumab

• easyho
• 10 Slides

as First-Line Therapy for Locally Recurrent or . M...

CASE 1: Management of metastatic disease in a resource-limited setting

• sialoquentburberry
• 15 Slides

Dr Sitna Mwanzi. Medical Oncologist. Aga Khan Univ...

Please note, these are the actual video-recorded

• chaptoe
• 71 Slides

proceedings from the live CME event and may includ...

TARGETED CANCER THERAPY IN 2016:

• bagony
• 14 Slides

WHAT THE PRACTICING PATHOLOGIST OR ONCOLOGIST NEED...

• thousandnike
• 39 Slides

actual. . video-recorded proceedings from the . l...

CURRICULUM VITAE PROFESSIONAL Current Position: Surgical and Nuclear

• white
• 28 Slides

PUBLICATIONS Peer Reviewed Articles, Turmen T: Con...

Module 9: HER2-Positive and

• norah
• 38 Slides

Triple-Negative Breast Cancer. Jamie Carroll, APRN...

MIB Agents OutSmarting Osteosarcoma Proposals

• jainy
• 15 Slides

1 2021 OutSmarting Osteosarcoma Finalist s Proposa...

CURRICULUM VITAE PROFESSIONAL Current Position Surgical and Nuclear

• riley
• 28 Slides

PUBLICATIONS Peer Reviewed Articles Turmen T Conge...

NasdaqVERU

• iris
• 45 Slides

VeruInc The Prostate Cancer Company Novel Medicine...

NasdaqVERU

• isabella2
• 37 Slides

VeruInc The Prostate Cancer Company Novel Medicine...

Modified LACE ToolDirections Points are assigned per category and tota

• eloise
• 1 Slides

AttributeValuePointsScorePrior AdmitLength of Stay...

Investigation of plasma hyaluronic acid and S100P as minimally invasiv

• riley
• 2 Slides

Cike PengDr schummarkers of metastatic breast canc...

NasdaqVERU

• kimberly
• 53 Slides

VeruInc Oncology Biopharmaceutical Company Focused...

Multimodality Therapy for

• emma
• 15 Slides

High Risk Disease – . The . Surgical Perspective...

Ano - uro -genital Mucosal Melanoma Guideline

• roberts
• 84 Slides

Instructions for using this slide set. White slide...